VTVT vTv Therapeutics Inc. Class A Common Stock
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
VTVT
—
—
Key stats
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.1B
- Employees
- 26
- List Date
- 2015-07-30
- CIK
- 0001641489
- Next Earnings
- 2026-11-05
- EPS Forecast
- ($1.07) (2 est.)
- Headquarters
- High Point, NC
- Homepage
- https://www.vtvtherapeutics.com
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 2.00% | -28.35% | 31.17% | -22.13% | 19.29% | -10.58% | -1.43% |
| Feb | 30.39% | 5.53% | -12.75% | 110.43% | 25.06% | -0.39% | 26.38% |
| Mar | 12.80% | -10.43% | -0.27% | 42.18% | -4.84% | 11.40% | 8.47% |
| Apr | -11.42% | 4.58% | -3.75% | 10.71% | 21.65% | -20.45% | 0.22% |
| May | -3.15% | -13.20% | 0.73% | -16.56% | -22.53% | 5.25% | -8.24% |
| Jun | -5.00% | 4.17% | -11.92% | -19.73% | -9.31% | 9.77% | -5.34% |
| Jul | -13.12% | 24.95% | -7.52% | -17.54% | 1.91% | -8.03% | -3.22% |
| Aug | -3.61% | 4.95% | -30.14% | 7.31% | 11.42% | -1.20% | -1.88% |
| Sep | -18.18% | -5.83% | -6.27% | -11.80% | 26.90% | -3.47% | -3.11% |
| Oct | -7.74% | -12.27% | -16.10% | 1.22% | -9.38% | -18.96%* | -10.54% |
| Nov | -13.29% | -7.06% | -12.89% | 14.33% | 14.10% | -- | -0.96% |
| Dec | -20.40% | -23.27% | -5.12% | -11.65% | 70.17% | -- | 1.95% |
| Total | -46.65% | -50.52% | -59.07% | 37.85% | 207.62% | -35.18% | 9.01% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $28.87
SMA 50: $30.80
SMA 200: $33.73
Current: $25.81
EMA 12: $27.54
EMA 26: $28.88
MACD: -1.3404 | Signal: -0.2605
BEARISH
ADX (14): 18.21
RANGE
+DI: 15.66
−DI: 29.50
Momentum Oscillators
RSI (14): 32.98
NEUTRAL
Stoch %K: 10.80
Stoch %D: 18.45
Williams %R: -92.51
Volume & Volatility
BB Upper: $32.68
BB Lower: $25.05
NEUTRAL
OBV: 191,866
Vol SMA 20: 25,427
Vol ROC: -11.71%
ATR: $1.42
True Range: $1.01
HV 20: 51.4%
HV 30: 44.8%
HV 60: 43.3%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-09T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report: VTVT
Executive Summary
Overall assessment: NEUTRAL with confidence level 6/10
Key drivers:
- Positive news sentiment driving price higher
- Technical indicators showing mixed signals, leaning towards range-bound trading
Primary risks:
- Recent high volatility suggesting increased uncertainty
- No earnings data available to provide context for potential future moves
2-3 sentence investment thesis: VTVT is a biotech company with promising pipeline candidates and strong recent news sentiment. However, the stock's current price action suggests it may be due for a consolidation period, potentially providing an attractive entry point for investors.
Recent news sentiment impact: Positive headlines have contributed to the stock's upward momentum, but a neutral market narrative suggests that further gains may be limited without additional catalysts.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): RANGE-BOUND, Medium-term (1-3 months): NEUTRAL, Long-term (3-12 months): BULLISH
Support/Resistance Levels: Key price levels include:
- Upper Bollinger Band: $34.82
- Middle Bollinger Band: $32.64
- Lower Bollinger Band: $30.46
Momentum Signals:
- RSI (14) = 53.34 (neutral)
- MACD signal line: 0.08 (bearish)
- Bollinger Bands position: neutral
Volume Analysis: Volume trends and institutional interest signals:
- Volume SMA 20: 60656.41
- On-Balance Volume (OBV): 355061.06
- Volume Rate of Change: -54.77%
News & Sentiment Analysis
Recent Headlines Summary: Positive news headlines related to the company's pipeline candidates and management appointments have driven the stock higher.
Sentiment Assessment: Aggregate news sentiment is POSITIVE, with all recent headlines conveying a positive narrative.
Catalyst Identification: No upcoming earnings or catalysts currently scheduled, but participation in investor conferences may provide an opportunity for investors to engage with management.
Risk & Volatility Assessment
Beta Interpretation: Beta 1.09 suggests the stock is more volatile than the broader market (SPY), but still relatively correlated.
Volatility Regime: Current volatility is above average compared to historical levels.
Options Market Signals: No options data available, but IV premium vs HV30 suggests implied volatilities are currently richer than realized.
Downside Protection: Support levels and risk management considerations:
- Lower Bollinger Band: $30.46
- Volume Rate of Change: -54.77%
Market Context & Positioning
Sector Performance: Relative strength within the healthcare sector, but lagging behind broader market trends.
Institutional Activity: Volume patterns suggest institutional interest is present, but not overly aggressive.
Correlation Analysis: The stock has a relatively low correlation with market (R-squared interpretation) = 0.19.
Relative Valuation: Position within trading range, potentially due for consolidation or breakout.
Key Levels & Action Items
Critical Price Levels:
- Upper Bollinger Band: $34.82
- Middle Bollinger Band: $32.64
- Lower Bollinger Band: $30.46
Breakout/Breakdown Levels: No specific levels currently, but potential range-bound trading may lead to consolidation.
Time-Sensitive Catalysts: Participation in investor conferences and upcoming news headlines may provide an opportunity for investors to engage with management or react to new developments.
Risk Management: Stop-loss levels and position sizing considerations:
- Lower Bollinger Band: $30.46
- Volume Rate of Change: -54.77%
Note: This analysis is a comprehensive report based on the provided data, but should not be taken as investment advice. It is essential to consult with a financial advisor or conduct your own research before making any investment decisions.
Generated
News
All VTVT news →
VTVT Options Activity & IV Rank
Loading options activity...
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 1.1107
Alpha: 31.52%
Correlation: 0.1946
R-Squared: 3.8%
Stock Volatility: 72.6%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 250
Period: 252 trading days
Data Points: 250
Period: 252 trading days
Interpretation:
Above average volatility - stock moves with market amplification
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
Notable investors who own VTVT
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $10.2M | #1561 of 3716 | +30.8% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $657K | #2497 of 3138 | new | 13F | |
| Point72 Hedge fund Steve Cohen | $224K | #1768 of 1945 | new | 13F | |
| Citadel Hedge fund Ken Griffin | $222K | #5377 of 6285 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
VTVT Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
VTVT Insider Trading (Form 4)
Latest: 2026-06-29Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-06-29 | Fahed Al-Marzooqi | Director | Grant (A) | +6,000 opt | — | EDGAR | |
| 2026-06-29 | Anne M. Phillips | Director | Grant (A) | +6,000 opt | — | EDGAR | |
| 2026-06-29 | 667, L.P. | Director | Grant (A) | +72,000 opt | — | EDGAR | |
| 2026-06-29 | Daniel K Spiegelman | Director | Grant (A) | +6,000 opt | — | EDGAR | |
| 2026-06-29 | Srinivas Akkaraju | Director | Grant (A) | +6,000 opt | — | EDGAR | |
| 2026-02-18 | Paul J Sekhri | Pres, CEO and Exec Chairperson | Grant (A) | +140,000 RSU | — | EDGAR | |
| 2026-02-18 | Michael Stephen Tung | EVP & CFO | Grant (A) | +44,969 opt | — | EDGAR | |
| 2025-09-25 | Srinivas Akkaraju | Director | Award (A) | +106,000 | $15.27 | $1.62M | EDGAR |
| 2025-09-05 | Felix Baker | Director | Award (A) | +306,000 | — | EDGAR | |
| 2025-09-05 | Srinivas Akkaraju | Director | Grant (A) | +1,311,046 RSU | — | EDGAR | |
| 2025-06-12 | Daniel K Spiegelman | Director | Grant (A) | +4,000 opt | — | EDGAR | |
| 2025-06-12 | Srinivas Akkaraju | Director | Grant (A) | +4,000 opt | — | EDGAR | |
| 2025-06-12 | Fahed Al-Marzooqi | Director | Grant (A) | +4,000 opt | — | EDGAR | |
| 2025-06-12 | Anne M. Phillips | Director | Grant (A) | +4,000 opt | — | EDGAR | |
| 2025-06-12 | 667, L.P. | Director | Grant (A) | +48,000 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
VTVT Insider Holdings
4 insiders · @ $25.81
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Samsara BioCapital GP, LLC | 10%+ Owner | 206,784 | $5.34M | $0 | 1 | 2024-12-06 |
| 2 | Srinivas Akkaraju | Director | 106,000 | $2.74M | $0 | 8 | 2026-06-29 |
| 3 | Felix Baker | Director | 12,368 | $319.2K | $0 | 2 | 2025-09-05 |
| 4 | Paul J Sekhri | Pres, CEO and Exec Chairperson | 5,000 | $129.1K | $83.8K | 4 | 2026-02-18 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
VTVT Board & Officers
As of SEC filings through Jun 29, 2026Directors 13
- Rich S. Nelson · since Nov 16, 2020
- Fahed Al-Marzooqi · since May 31, 2022
- Paul J Sekhri · since Aug 1, 2022
- Srinivas Akkaraju · since Feb 23, 2024
- 667, L.p. (entity) · since Feb 27, 2024
- Baker Bros. Advisors (GP) LLC (entity) · since Feb 27, 2024
- Baker Bros. Advisors LP (entity) · since Feb 27, 2024
- Baker Brothers Life Sciences LP (entity) · since Feb 27, 2024
- Felix Baker · since Feb 27, 2024
- Julian Baker · since Feb 27, 2024
- Raymond Cheong · since Feb 27, 2024
- Anne M. Phillips · since Mar 13, 2024
- Daniel K Spiegelman · since Jun 11, 2024
Officers 2
- Paul J Sekhri · Pres, CEO and Exec Chairperson · listed since Nov 2024
- Michael Stephen Tung · EVP & CFO · since May 19, 2025
Changes in the last 10 years (48)
| May 19, 2025 | Michael Stephen Tung became EVP & CFO |
| Apr 24, 2025 | Srinivas Akkaraju no longer listed as a 10% owner in SEC filings |
| Feb 24, 2025 | The company announced the departure of Steven L. Tuch as Chief Financial Officer in an SEC filing |
| Dec 6, 2024 | Samsara BioCapital, L.P. reported in an SEC filing no longer being a 10% owner |
| Dec 6, 2024 | Samsara BioCapital GP, LLC reported in an SEC filing no longer being a 10% owner |
| Nov 19, 2024 | Paul J Sekhri listed as Pres, CEO and Exec Chairperson (previously President and CEO) in SEC filings |
| Jun 11, 2024 | Daniel K Spiegelman became a director |
| Mar 13, 2024 | Anne M. Phillips became a director |
| Feb 27, 2024 | Samsara BioCapital, L.P. became a 10% owner |
| Feb 27, 2024 | Samsara BioCapital GP, LLC became a 10% owner |
| Feb 27, 2024 | Raymond Cheong became a director |
| Feb 27, 2024 | Julian Baker became a director |
| Feb 27, 2024 | Felix Baker became a director |
| Feb 27, 2024 | Baker Brothers Life Sciences LP became a director |
| Feb 27, 2024 | Baker Bros. Advisors LP became a director |
| Feb 27, 2024 | Baker Bros. Advisors (GP) LLC became a director |
| Feb 27, 2024 | 667, L.p. became a director |
| Feb 23, 2024 | The company announced the departure of Keith R. Harris from the board in an SEC filing |
| Feb 23, 2024 | The company announced the departure of Jonathan Isaacsohn from the board in an SEC filing |
| Feb 23, 2024 | The company announced the departure of John A Fry from the board in an SEC filing |
| Feb 23, 2024 | The company announced the departure of Howard L. Weiner from the board in an SEC filing |
| Feb 23, 2024 | The company announced the departure of Hersh Kozlov from the board in an SEC filing |
| Feb 23, 2024 | Srinivas Akkaraju became a director |
| Feb 23, 2024 | Srinivas Akkaraju became a 10% owner |
| Dec 18, 2023 | The company announced the departure of Chandresh Harjivan from the board in an SEC filing |
| Dec 8, 2022 | Steven L. Tuch became Chief Financial Officer |
| Aug 9, 2022 | Jonathan Isaacsohn became a director |
| Aug 1, 2022 | Paul J Sekhri became a director |
| Aug 1, 2022 | Paul J Sekhri became President and CEO |
| Jul 11, 2022 | Keith R. Harris became a director |
| Jun 1, 2022 | Chandresh Harjivan became a director |
| May 31, 2022 | Tahnoon Bin Zayed S. Al-Nahyan became a 10% owner |
| May 31, 2022 | G42 Investments AI Holdings RSC Ltd. became a director |
| May 31, 2022 | G42 Investments AI Holdings RSC Ltd. became a 10% owner |
| May 31, 2022 | Fahed Al-Marzooqi became a director |
| Mar 30, 2022 | The company announced the departure of Noel Joseph Spiegel from the board in an SEC filing |
| Mar 29, 2022 | Barry K. Brown became Chief Accounting Officer |
| Mar 4, 2022 | Rich S. Nelson first listed as Acting Chief Executive Officer in an SEC filing |
| Feb 27, 2022 | The company announced the departure of Deepa Prasad as President and CEO in an SEC filing |
| Dec 1, 2021 | The company announced the departure of Rudy Howard as CFO & Secretary in an SEC filing |
| Oct 19, 2021 | Deepa Prasad became a director |
| Oct 19, 2021 | Deepa Prasad became President and CEO |
| Dec 30, 2020 | Robin Elizabeth Abrams became a director |
| Nov 16, 2020 | Rich S. Nelson became a director |
| Aug 31, 2020 | Edward P. Taibi became a director |
| Dec 3, 2019 | Jeffrey B Kindler no longer listed as Executive Chairman in SEC filings |
| Sep 11, 2019 | Hersh Kozlov became a director |
| Jul 31, 2017 | Howard L. Weiner became a director |
Not reported recently (12)
- Barry K. Brown · Last reported as Chief Accounting Officer in an SEC filing dated Apr 11, 2025
- Tahnoon Bin Zayed S. Al-Nahyan · Last reported as a 10% owner in an SEC filing dated Jun 23, 2022
- G42 Investments AI Holdings RSC Ltd. · Last reported as a director in an SEC filing dated Jun 10, 2022
- Ronald O Perelman · Last reported as a 10% owner in an SEC filing dated Dec 21, 2021
- Deepa Prasad · Last reported as a director in an SEC filing dated Oct 21, 2021
- Robin Elizabeth Abrams · Last reported as a director in an SEC filing dated Dec 30, 2020
- Stephen L. Holcombe · Last reported as President & CEO in an SEC filing dated Dec 9, 2020
- Edward P. Taibi · Last reported as a director in an SEC filing dated Sep 3, 2020
- Jeffrey B Kindler · Last reported as a director in an SEC filing dated Jun 15, 2020
- Paul G Savas · Last reported as a director in an SEC filing dated Sep 6, 2018
- Craig C Parker · Last reported as a director in an SEC filing dated May 2, 2018
- Larry Douglas Altstiel · Last reported as Chief Medical Officer in an SEC filing dated Mar 14, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
VTVT Proposed Insider Sales (Form 144)
Latest: 2025-05-01
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2025-05-01 | STEVEN TUCH | Officer | 1,258 | $25.2K | 2025-05-01 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2025-04-29 | STEVEN TUCH | Officer | 1,000 | $21.5K | 2025-04-29 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2025-04-24 | STEVEN TUCH | Officer | 1,000 | $21.5K | 2025-04-24 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
5 ETFs hold VTVT
5 shown · $2.73M total exposure · 0.00% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $1.9M | — | 2026-09-30 |
| 2 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $576,060 | — | 2026-09-30 |
| 3 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.01% | $168,886 | $1.2B | 2026-10-23 |
| 4 | QQQS Invesco NASDAQ Future Gen 200 ETF | Invesco | 0.45% | $92,236 | — | 2026-10-24 |
| 5 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.00% | $14,717 | $3.2B | 2026-10-23 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.